article thumbnail

‘The Doors are Wide Open’: Denver Cannabis Company Gets DEA Approval To Expand Alzheimer’s Research

Cannabis Law Report

We’re interested in how cannabinoids affect the nervous system, the brain, and in in particular, we’re very interested in Alzheimer’s disease,” said Dr. Tyrell Towle, director of chemistry and extraction at MedPharm. According to Towle, MedPharm’s researchers hope to find whether cannabinoids can treat symptoms or even prevent the disease.

DEA 105
article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.

DEA 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 66
article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

article thumbnail

Denver Cannabis Company to Expand Alzheimer’s Research

SpeedWeed

We’re interested in how cannabinoids affect the nervous system, the brain, and in particular, we’re very interested in Alzheimer’s disease,” said Dr. Tyrell Towle, director of chemistry and extraction at MedPharm. Denver Company Moves Forward with Research License . Denver’s MedPharm Drives Research Further. “We

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

Drug Enforcement Agency (DEA). We could potentially develop north of 11,000 drugs that are cannabinoid-based. According to the company’s CEO, George Hodgin, “federally legal FDA- and DEA-approved cannabis-based drugs will absolutely upend the traditional pharmaceutical market.”. Is the future exciting? Absolutely.”

article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA.